Pharma Industry
Industry: Email Alert RSS FeedProspective study using remicade in psoriasis patients with an inadequate response to etanercept
Journal of Drugs in Dermatology, March, 2008
Sponsored by: Centocor, Inc. The purpose of this study is to test the safety and effectiveness of infliximab in patients with plaque psoriasis who have been receiving the drug etanercept for treatment of their plaque psoriasis for at least 4 months, without enough improvement in their psoriasis symptoms.
Condition Intervention Phase Psoriasis Biological: infliximab Phase III
Study ID Numbers: CR014500, C0168Z04
Most RecentPharma Articles
- Can Talcum Powder Give You Cancer? J&J Is About to Find Out
- GSK's $1B Paxil Problem Highlights Murky Disclosures From Euro Drug Companies
- Drug Pricing Debate: Same Story, Different Day...Any Bets on the Outcome?
- How Much To Extend Life? Allos Therapeutics Says $30,000 per Month
- Abbott Labs' Deal with Teva Pharma Is 'Phat News' for Lipid-Lowering Franchise
- More »
ClinicalTrials.gov Identifier: NCT00527072
Brought to you by CBS MoneyWatch.com
- Best- and Worst-Paid College Degrees
- 6 Things You Should Never Do on Twitter or Facebook
- How Much Sleep Do You Really Need?
- 6 Big Myths about Gas Mileage
Most Recent Health Articles
Most Recent Health Publications
Most Popular Health Articles
- Make running easier: with this unique 'pose running' technique, you'll learn to actually enjoy your fat-burning sessions
- 50 home remedies that work: these safe, fast, and effective fixes will relieve what ails you - Cover Story
- Detox in 7 days: a detoux diet can help you shed up to 10 pounds and leave you feeling terrific. Our weeklong plan shows you how to lose the weight and keep it off - Cover story
- Treat sinusitis naturally: breath easy and relieve sinus pressure with these remedies - Quick Fixes and Long-Term Solutions
- All about nightshades: explore the hidden hazards of your favorite food with macrobiotic nutritionist Lino Stanchich



